Q1 Earnings Forecast for DWTX Issued By HC Wainwright

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Dogwood Therapeutics in a report released on Tuesday, May 19th. HC Wainwright analyst S. Lee expects that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.15) EPS and Q4 2027 earnings at ($0.15) EPS.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its earnings results on Thursday, May 14th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07.

Separately, Weiss Ratings lowered Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Dogwood Therapeutics has an average rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Price Performance

Shares of NASDAQ DWTX opened at $1.85 on Wednesday. The business has a 50-day moving average of $2.05 and a two-hundred day moving average of $3.56. The company has a market capitalization of $62.22 million, a price-to-earnings ratio of -0.17 and a beta of 1.68. Dogwood Therapeutics has a 1 year low of $1.28 and a 1 year high of $9.50.

Institutional Investors Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 9.05% of the stock is currently owned by institutional investors and hedge funds.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.